Cognigenics' Intranasal CRISPR Delivery Bypasses Blood-Brain Barrier; Potential Breakthrough Therapeutic
- Nasdaq outperforms on Alphabet boost, payrolls data in focus
- Stocks could be in 'panic' mode in 2024, warns JPM's Kolanovic
- Can S&P 500 rally without the Magnificent 7 leading the way? 'Easy' says BofA
- Analysts remain cautious on Chewy as shares drop 10% weak guidance
- AI sentiment toward Google seen improving rapidly after Gemini launch; Shares gain
Study: method reduced anxiety with no apparent toxicity or neurologic damage
BOISE, Idaho--(BUSINESS WIRE)-- Cognigenics CEO John L. Mee announces breakthrough results from an animal study published today in PNAS Nexus. The findings point to the potential of non-invasively delivering neuromodulating gene therapies to the brain for chronic mental health conditions using adeno-associated viruses introduced intranasally.
"Our patent-pending CRISPR/Cas9 delivery system enabled us to bypass the blood-brain barrier by intranasally administering therapeutics to reach the central nervous system via the neural pathways in the nasal cavity,” said Director of Preclinical Studies Troy Rohn, PhD, principal investigator of the study. “In the study, a single dose significantly reduced anxiety in mice, demonstrating that complex behavioral traits can be directly modified by this non-invasive technique.”
Chief Medical Officer Barry J. Linder, MD added, "While our findings are preliminary, they may lead to a new class of long-lasting therapeutics with fewer side effects than SSRIs for mental health conditions including anxiety, depression and ADHD, as well as for some genetic conditions."
Significant reduction in anxiety
The animal study tested a platform of CRISPR/Cas9 utilizing two adeno-associated viruses (AAVs) to deliver anti-anxiety reagents in vivo to the part of the brain that is overactive in anxiety. The method requires two delivery vectors because of the limited cargo capacity of the viruses. Each virus was modified using Cognigenics' proprietary CRISPR gene-editing technology.
Treated mice showed 35.7% and 14.8% decreases in two standard measures of anxiety.
No toxicity or neurologic damage
Importantly, there was no evidence of toxicity at any concentration following treatment, and neurons were healthy.
About CRISPR technology
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary genetic technology that allows precise editing of DNA. It functions like molecular scissors, cutting DNA at a specific location and allowing researchers to add, remove, or replace specific sections of genetic code. CRISPR has the potential for treating a wide range of genetic diseases and mental health conditions.
Founded in 2019, Cognigenics works at the forefront of genetic neuroengineering through patent-pending CRISPR technology to precisely and noninvasively target and modulate the underlying neural circuits responsible for mental health disorders such as anxiety, depression, ADHD, and some forms of cognitive impairment.
Learn more at www.cognigenics.io.
Dean Radin, PhD
John L. Mee
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Suffolk Announces Launch of Sustainability Group, Positioning the Firm as a National Leader in Green Construction
- Boussard & Gavaudan Holding Ltd (EUR): Newsletter November 2023
- KBRA Assigns Preliminary Ratings to Brean Asset Backed Securities Trust 2023-RM7 (BABS 2023-RM7)
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!